Discussion  by unknown
those we report, a multi-institutional comprehensive pa-
tient-oriented database would be needed. Because this
study spans 19 years and multiple examining pathologists,
we reported pathologic findings based on a simple stan-
dard of CR, PR, and NR rather than the more detailed de-
scriptor of percentage of viable cells in the specimen. A
final limitation of the study is that because of its retro-
spective nature, the time to recurrence (and location of re-
currences) could have been impacted by the fastidiousness
of monitoring.
The findings of this study, and others,16 suggest that not
all esophageal carcinomas are equal and that rather than
more aggressive chemotherapy regimens, or more inten-
sive radiation dosing schedules, efforts must be made to
target different tumors with chemotherapeutic agents to
which they are sensitive. This new era of ‘‘personalizing’’
or customizing chemotherapeutic and radiation regimens
to specific molecular targets in the primary tumor is
now upon us, and because of the success of the neoadju-
vant therapy approach in esophageal cancer, this is an ap-
propriate cancer model to test these innovations.
Importantly, this study emphasizes the critical role of neo-
adjuvant chemotherapy in ‘‘eliminating’’ distant disease
outside of the local surgery and radiation fields and offers
yet more evidence that ultimately the control of distant
disease is critical in preventing esophageal cancer recur-
rence. Patients who experience a CR to neoadjuvant ther-
apy have the best outcomes in terms of lowest incidence
of recurrence, longest disease-free survival, and longest
overall survival.
The authors would like to acknowledge the Hosler Family, the
Thorn Family, the family of Mr Robert Carollo, and the family of
Mrs Catherine Remmert whose generous contributions have sup-
ported this research.
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Dr Michael Weyant (Aurora, Colo). Good morning. I would
like to first thank the Western for inviting me to discuss this paper,
and I would also like to thank the authors for sending me the man-
uscript well in advance.
In our evolution of the treatment of patients with locally ad-
vanced esophageal malignancy, trimodality therapy has emerged
as the standard of care in this group of patients, with preoperative
chemoradiation being the standard. What has emerged out of all
this is the 3 groups of patients that you illustrated so nicely here,
the patients with complete response responding better than either
the patients with partial response or those with no response.
Your work illustrates the patterns of recurrences, which is also
extremely valuable because it is work like this that will help guide
future studies regarding the therapy of these patients as well.
I just have 3 brief questions for you.
First, I would like to knowwhat your standard stagingmodalities
are in the pretreatment setting for guiding your therapy of these pa-
tients.
DrMeguid (Baltimore, Md). Although there has been an evolu-
tion of about 15 years between the first patients and our most recent
patients, currently we are obtaining high-resolution CT scans of all
patients. We are also increasingly using positron emission tomog-
raphy scans and endoscopic ultrasound to stage patients.
Dr Weyant. My second question ties into that, knowing that
you are using the modern staging modalities. In the manuscript
you sent me, in the characterizations of your preclinically staged
patients, you had 26 patients who were clinically staged as stage
IV and conversely you had a group of patients of 12, I believe,
who were stage I that you did not illustrate in your talk. The ques-
tions are, what is the rationale and what are the characteristics of
those patients in stage IV that actually led them to get surgery,
and then conversely, what is the rationale for the group of pa-
tients in stage I to get the neoadjuvant therapy and then surgery
as well?
Dr Meguid. I agree these are very valid points.
Those are all patients who got neoadjuvant therapy and surgery,
and included in our series. At our institution, we offer neoadjuvant
therapy and surgery to patients with Stage IVa disease.
These are limitations to our preliminary study, and we need to
resolve these before we pursue this as a publication.urgery c December 2009
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SDrWeyant.The last question is, and you briefly alluded to the dif-
ference between squamous carcinomas and adenocarcinomas. There
is a general belief that they behave very differently and respond dif-
ferently to neoadjuvant therapy. Did you do any subset analysis look-
ing at the 2 subgroups regarding complete response and survival?
Dr Meguid. Yes, actually this is in the manuscript revised
since we sent it to you. In brief, the patients with nonresponding
squamous cell carcinoma did very poorly and died very rapidly,
whereas the patients with squamous cell carcinoma whom re-
sponded had relatively favorable outcomes, and have not yet
reached 50% mortality. The differences in patients with adenocar-
cinoma are less pronounced than this. Again, we have done a se-
ries of subanalyses and are currently trying to identify which
different relationships exist.
DrDavid Follette (Sacramento, Calif). That was a superbly pre-
sented paper. I am always pleased to see when studies validate other
work. The subset of your squamous cell carcinoma certainly vali-
dates some work from East Germany that showed in a group of pa-
tients showing complete response with squamous cell carcinomas
there was approximately 70% 5-year survival. I think your valida-
tion of that work is very important and in a way validates some of
your conclusions, notwithstanding the homework you are going to
do when you get back.
Having said that, it is like what we were talking about yesterday
with lung cancer. At Baltimore, do you do any restaging after neo-
adjuvant chemoradiation?
Dr Meguid.We do some restaging, mostly the 50% of our pa-
tients who get their neoadjuvant therapy at outside institutions. In
this study, we did not look at that restaging. We looked at patients’
preneoadjuvant staging and their postoperative pathologic staging
to make a comparison as to who was downstaged, who showed
no response, and who had a complete response.
Dr Follette. Because as you know, we have no prospective ran-
domized trials validating neoadjuvant treatment, but if we begin to
look—and Tom Rice has pointed this out to us on numerous occa-
sions. Nodal disease is really a poor indicator.
My second question, when you are talking about complete re-
sponse, you are talking about both the tumor and no positive nodes
in the surgical specimen?
Dr Meguid. That is correct. There is no evidence of disease in
the surgical specimen.
Dr Follette. I appreciate a very well-presented paper, and I be-
lieve your results are going to help all of us in the debate aboutThe Journal of Thoracic and Cneoadjuvant treatment and its value in that subset of patients who
show complete response.
Dr Robert Cerfolio (Birmingham, Ala). Very well presented.
Two quick questions, because I see the time is short. Do you
have maximum standardized uptake value data in the people who
got the positron emission tomography, the change in the maximum
standardized uptake value?
Dr Meguid. We do not have that data in our database.
Dr Cerfolio. So can I look forward then to seeing it in the man-
uscript?
Dr Meguid. No, it won’t be.
Dr Cerfolio. Okay, the second question is: I love to come to
these meetings because I learn stuff and I take it back. You heard
how I changed my practice with Dr Lowe’s article a few years
ago. How is this paper going to change my practice? What am I go-
ing to do differently?
DrMeguid. This may change what you tell your patients. If you
have female patients, if you have patients with squamous cell
esophageal adenocarcinoma, you may be able to tell them they
are more likely to show complete response than male patients or pa-
tients with adenocarcinoma. That is in the short run. In the long run,
I believe this is leading us more to look at tumor biology differences
and try to identify what we can do to appropriately target patients
with better chemotherapeutic regimens so that we can ultimately
have more clinical complete responses as opposed to just continu-
ing the same trends we have been doing.
Dr James Stewart (Colorado Springs, Colo). As a 20-year vet-
eran of advocating neoadjuvant chemoradiation for esophageal
cancer, we noticed about 15 years ago that patients showing partial
response just did not do as well, and although I have not published
any information, we developed some postoperative treatment strat-
egies for those patients and wondered if you had also adopted
something similar.
Dr Meguid. That is an interesting observation. In fact, patients
showing partial response do almost as poorly as those showing no
response, such that in the abstract in the meeting program, we com-
bined them because they have similarly dismal outcomes. Our pa-
tients—about 20% of all the groups, with no statistically significant
difference between the groups—received postoperative chemother-
apy. I do not believe it resulted in a difference in the 3 treatment
groups. As of yet, we have not been able to identify, up front, pa-
tients whom are going to have partial response versus those going
to have no response, unfortunately.ardiovascular Surgery c Volume 138, Number 6 1317
